Rekombinanter CCR2 (Plozalizumab Biosimilar) Antikörper
Research Grade
Reaktivität: Human
ELISA
Wirt: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target Alle CCR2 (Plozalizumab Biosimilar) Produkte
- CCR2 (Plozalizumab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
-
Wirt
-
Mammalian Cells
- Expressionssystem
- Mammalian cells
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser CCR2 (Plozalizumab Biosimilar) Antikörper ist unkonjugiert
-
Applikation
- ELISA
- Verwendungszweck
- Plozalizumab Biosimilar - Anti-CCR2, CD192 mAb
- Produktmerkmale
- Antibody Type: IgG1-kappa
- Aufreinigung
- Recombinant antibody expressed in mammalien cells and purified.
- Güteklasse
- Research Grade
- Isotyp
- IgG1 kappa
-
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- PBS pH 7.5
- Lagerung
- -80 °C
- Informationen zur Lagerung
- store at -80°C
-
- Target
- CCR2 (Plozalizumab Biosimilar)
- Abstract
- CCR2 (Plozalizumab Biosimilar) Produkte
- Substanzklasse
- Biosimilar
- Hintergrund
-
MLN-1202,anti-CCR2,hu1D9
Plozalizumab is a humanized monoclonal antibody that targets CCR2 chemokine receptors found on the surface of white blood cells such as macrophages and monocytes. Plozalizumab has been investigated to treat Atherosclerosis. CCR2 is supposed to play an important role in the trafficking of monocytes and macrophages to sites of inflammation. - CAS-Nummer
- 1610761-46-0
-
Sie sind hier:
